Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

BACKGROUND: BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment of moderate or severe opioid use disorder. The primary objective of this phase III study was to assess the lon...

Descripción completa

Detalles Bibliográficos
Autores principales: Andorn, Anne C., Haight, Barbara R., Shinde, Sunita, Fudala, Paul J., Zhao, Yue, Heidbreder, Christian, Learned, Susan M., Fox, Norma Lynn, Nadipelli, Vijay R., Hassman, David, Rutrick, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188268/
https://www.ncbi.nlm.nih.gov/pubmed/32282418
http://dx.doi.org/10.1097/JCP.0000000000001195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188268/
https://www.ncbi.nlm.nih.gov/pubmed/32282418
http://dx.doi.org/10.1097/JCP.0000000000001195

Ejemplares similares